{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:55:06Z","timestamp":1789419306112,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002001","name":"Campbell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymthe.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:34:14Z","timestamp":1775842454000},"page":"3217-3223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-in-human intracisternal dosing of RGX-111 in severe MPS I is well tolerated and generates sustained neurodevelopment without HSCT"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-7613","authenticated-orcid":false,"given":"Raymond Y.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Movsesyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hsin","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammam","family":"Beydoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mery","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gilmor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonjin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Falabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.04.016_bib1","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"The Mucopolysaccharidoses","author":"Neufeld","year":"2019"},{"key":"10.1016\/j.ymthe.2026.04.016_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.04.016_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10545-013-9613-3","article-title":"Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity","volume":"37","author":"Archer","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.04.016_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2026.04.016_bib5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","article-title":"Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison","volume":"20","author":"Eisengart","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2026.04.016_bib6","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.04.016_bib7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2026.04.016_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.016_bib9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2019.012","article-title":"Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys","volume":"30","author":"Hordeaux","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.016_bib10","series-title":"REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs","year":"2026"},{"key":"10.1016\/j.ymthe.2026.04.016_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13023-018-0817-3","article-title":"Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome","volume":"13","author":"Shapiro","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2026.04.016_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1172\/JCI112830","article-title":"Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system","volume":"79","author":"Shull","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.04.016_bib13","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.04.016_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020189","article-title":"Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement","volume":"11","author":"Hampe","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2026.04.016_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jimd.12598","article-title":"Persistent bone and joint disease despite current treatments for mucopolysaccharidosis types I, II, and VI: Data from a 10-year prospective study","volume":"46","author":"Miller","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.04.016_bib16","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.04.016_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi8214","article-title":"Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome","volume":"16","author":"Consiglieri","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.04.016_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymthe.2025.09.042","article-title":"Non-neurological, non-skeletal outcomes after hematopoietic stem and progenitor cell-gene therapy (OTL-203) for Hurler syndrome","volume":"34","author":"Tucci","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.016_bib19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14712598.2025.2606047","article-title":"From trial to transformation: insights into hematopoietic stem cell-gene therapy for Hurler syndrome","volume":"25","author":"Tucci","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2020.12.040","article-title":"Clinical and numerical presentation of neurocognitive assessments for MPS II patients using the Bayley Scales of Infant Development- version 3 (BSID-III)","volume":"132","author":"Cho","year":"2021","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:18:32Z","timestamp":1788178712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626002820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525001626002820"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.016","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human intracisternal dosing of RGX-111 in severe MPS I is well tolerated and generates sustained neurodevelopment without HSCT","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}